THE COMPANY

Building the next generation of personalized immunotherapy

Odimma Therapeutics is a biotechnology company developing precision immunotherapy approaches designed around the biology of each individual patient.

The company started around the vision that the future of immunotherapy lies in personalized therapeutic design — integrating biology, data and synthetic engineering into clinically actionable approaches.

Every patient carries
a different biological story.

Precision medicine should respond to it.

Integrating biology, AI and synthetic DNA engineering into personalized therapeutic development

A platform-driven biotechnology company

————

Odimma Therapeutics is developing a precision immunotherapy platform designed to support personalized therapeutic strategies across multiple clinical settings.

The company’s initial clinical focus is oncology, with ODI-2001 representing the first therapeutic program emerging from the platform.

Leadership

___

Odimma Therapeutics brings together expertise across oncology, immunology,
pharmaceutical development, regulatory strategy and personalized medicine.

Jean-Marc Limacher, MD

Chairman, Co-Founder, CMO
Medical Oncologist & Cancer Geneticist

Jean-Marc Limacher is a medical oncologist and cancer geneticist. He began his career at the University Hospitals of Strasbourg, where he established the institution’s cancer family clinic dedicated to hereditary cancer management.

In 2004, he joined Transgene as Medical Director, where he led the clinical development of several cancer immunotherapy programs. His work in oncology and immunotherapy has contributed to more than 60 scientific publications.

In 2016, he filed a patent application for an innovative personalised immunotherapy platform, which led to the co-founding of Odimma Therapeutics in 2017. He currently serves as Chairman and Chief Medical Officer of Odimma Therapeutics.

Scientific & Pharmaceutical Development Team

———

Jérémy Amzallag

———
PharmD, Qualified Person

Jérémy Amzallag, PharmD, is an industrial pharmacist specializing in pharmaceutical quality assurance, GMP manufacturing and clinical batch release. Founder of EYLIO and Qualified Person (QP), he supports biotechnology companies in ensuring regulatory compliance and the release of investigational medicinal products for clinical trials. With extensive experience in pharmaceutical quality systems, GMP compliance and batch certification, Jérémy brings deep expertise across the clinical manufacturing lifecycle.

At Odimma Therapeutics, he supports the company’s quality assurance, CMC activities and regulatory strategy, helping prepare future clinical batches in accordance with European regulatory standards.

Ronald Rooke, PhD

———
Scientific Affairs, Immunology and Oncology.

Ronald Rooke, PhD, holds a doctorate in Microbiology and Immunology from McGill University and has dedicated his career to the application of immunology in oncology and cancer immunotherapy. Formerly Director of Immunopharmacology at Transgene, he led the development of preclinical models supporting MVA-based therapeutic cancer vaccines.
With extensive expertise in tumor immunology, translational research, biomarker development and clinical support, Dr. Rooke also brings experience in the development of immunostimulatory small molecules. At Odimma Therapeutics, he provides scientific guidance for the development and validation of the company’s next-generation personalized immunotherapy platform.

Pascale Balducchi

———
Partner Consultant – Strategy & Business.

Pascale Balducchi, DVM, MBA, is a veterinarian specialized in toxicology with more than 30 years of experience in pharmaceutical research, oncology, biotechnology strategy and business development. She held senior positions at Sanofi and Pierre Fabre Oncology, contributing to the clinical development and international launch of pharmaceutical products across Europe and the United States.

Pascale has advised numerous biotech companies on fundraising, strategic partnerships and corporate development, particularly in oncology and immuno-oncology. Since 2021, she has served as Partner at Odimma Therapeutics, supporting the company’s business development, strategic partnerships and growth initiatives.

Delphine Courade

———
Clinical Supply Management.

Delphine Courade is a project manager specialized in pharmaceutical development and clinical supply operations, with extensive experience supporting biotechnology and pharmaceutical companies throughout the clinical development process.

Her expertise includes clinical supply chain management, project coordination, manufacturing oversight and regulatory compliance, ensuring the efficient execution of complex development programs.

Through EYLIO, Delphine supports Odimma Therapeutics in coordinating subcontractors involved in the manufacturing and supply chain activities required for the company’s clinical-stage products.

Rémi Gloeckler, PhD

———
Partner – Pharmaceutical Development – Biologist.

Rémi Gloeckler is an expert in pharmaceutical development, GMP manufacturing and quality control of advanced biotherapies, with more than 30 years of experience in the biotechnology and pharmaceutical industries. As founder and CEO of PharminCell, he supports biotech companies in the pharmaceutical development and regulatory readiness of innovative therapeutic products.
His expertise spans CMC strategy, process development, technology transfer, GMP manufacturing and regulatory compliance for advanced therapy medicinal products (ATMPs). At Odimma Therapeutics, Rémi provides strategic guidance on pharmaceutical development and manufacturing activities, ensuring the company’s personalized immunotherapy platform meets the highest quality and regulatory standards for clinical development.

Célia Matta, PhD

———
Preclinical Research & Development, Laboratory operations.

Célia Matta, PhD, holds a doctorate in Life and Health Sciences from the University of Strasbourg and specializes in preclinical research and laboratory operations within the biotechnology field.

As Preclinical Research Officer at Odimma Therapeutics, she supports the company’s immunotherapy development programs by coordinating preclinical research activities and laboratory operations.

She also oversees the implementation of Health, Safety and Environment (HSE) standards, ensuring that all laboratory activities are conducted in compliance with regulatory requirements and best scientific practices.

Nicolas Ferry, MD, PhD

———
Regulatory Affairs
Former biologics director at ANSM and former EMA CAT member.

Nicolas Ferry, MD, PhD, is a physician-scientist with more than 30 years of experience in advanced biotherapies, regulatory affairs and translational medicine. A former senior scientist at INSERM, he has co-authored more than 120 scientific publications and has played a leading role in the development of innovative gene and cell therapies.
From 2011 to 2016, he served as Director for Biologics at the French National Agency for Medicines and Health Products Safety (ANSM) and as a member of the Committee for Advanced Therapies (CAT) at the European Medicines Agency (EMA). At Odimma Therapeutics, Nicolas provides strategic guidance on regulatory affairs, pharmaceutical development and clinical translation, supporting the advancement of the company’s next-generation immunotherapy platform.

Margaux Longuespée, PhD

———
Pharmaceutical Quality.

Margaux Longuespée, PhD, holds a doctorate in Analytical Sciences and combines a strong scientific background with expertise in quality management, clinical development and regulatory affairs within the biotechnology sector.

She began her career at the German Cancer Research Center (DKFZ) and Heidelberg University Hospital, contributing to translational research in oncology and personalized medicine.

Through EYLIO, Margaux supports Odimma Therapeutics in the preparation and quality oversight of Clinical Trial Application (CTA) documentation, helping ensure regulatory compliance and the successful advancement of the company’s clinical development program.

Strategic Board

———

Jean-Marc Limacher, MD

———

Chairman & CMO, Odimma Therapeutics

Jean-Yves Bonnefoy, PhD

———

Chairman of Syndivia, France

Patrick Squiban, MD

———

CEO of Health and Biotech France

Peter de Waele, PhD

———

Vice-President R&D and IP at Celyad, Belgium

Virginia Math

———

Investment Director Capital Grand-Est

our partners

——————————————————

Built Through

Strategic Partnerships

Odimma Therapeutics collaborates with leading biotechnology, genomic sequencing, manufacturing and clinical organizations to support the development of scalable personalized immunotherapy platforms.